Use of second treatment following definitive local therapy for prostate cancer: Data from the capsure database

Journal of Urology

Volumn 160, Issue 4, 1998, Pages 1398-1404

  Grossfeld, Gary D ^a   Stier, David M ^a   Flanders, Scott C ^a   Henning, James M ^a   Schonfeld, Warren ^a   Warolin, Karen ^a   Carroll, Peter R ^a  

^a NONE

Author keywords

Cryosurgery; Prostatectomy; Prostatic neoplasms; Radiation

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CRYOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL; TREATMENT PLANNING;

EID: 0032324222     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62548-5     Document Type: Article

References (29)

1. Lu-Yao, G. L., Potosky, A. L., Albertsen, P. C., Wasson, J. H., Barry, M. J. and Wennberg, J. E.: Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J. Natl. Cancer Inst., 88: 166, 1996.
2. Catalona, W. J. and Smith, D. S.: 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol., 152: 1837, 1994.
3. Walsh, P. C., Partin, A. W. and Epstein, J. I.: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol., 152: 1831, 1994.
4. Coogan, C. L. and McKiel, C. F.: Percutaneous cryoablation of the prostate: preliminary results after 95 procedures. J. Urol., 154: 1813, 1995.
5. Connolly, J. A., Shinohara, K., Presti, J. C., Jr. and Carroll, P. R.: Prostate-specific antigen after cryosurgical ablation of the prostate. Defining the appropriate response. Urol. Clin. N. Amer., 24: 415, 1997.
6. Critz, F. A., Levinson, K., Williams, W. H., Holladay, D., Holladay, C. and Griffin, V.: Prostate-specific antigen nadir of 0.5 ng./ml. or less defines disease freedom for surgically staged men irradiated for prostate cancer. Urology, 49: 668, 1997.
7. Geist, R. W.: Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate. Urology, 45: 1016, 1995.
8. Lee, W. R., Hanlon, A. L. and Hanks, G. E.: Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease free survival. J. Urol., 156: 450, 1996.
9. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Rad. Oncol. Biol. Phys., 37: 1035, 1997.
10. Lubeck, D. P., Litwin, M. S., Henning, J. M., Stier, D. M., Mazonson, P., Fisk, R. and Carroll, P. R.: The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel, Cancer of the Prostate Strategic Urologie Research Endeavor. Urology, 48: 773, 1996.
11. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E., Scardino, P. T. and Pearson, J. D.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. J.A.M.A., 277: 1445, 1997.
12. Bauer, J. J., Connelly, R. R., Sesterhenn, I. A., Bettencourt, M. C., McLeod, D. G., Srivastava, S. and Moul, J. W.: Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer, 79: 952, 1997.
13. Ohori, M., Goad, J. R., Wheeler, T. M., Eastham, J. A., Thompson, T. C. and Scardino, P. T.: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J. Urol., 152: 1843, 1994.
14. Pisansky, T. M., Kahn, M. J., Rasp, G. M., Cha, S. S., Haddock, M. G. and Bostwick, D. G.: A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer, 79: 337, 1997.
15. Zagars, G. K., Pollack, A., Kavadi, V. S. and von Eschenbach, A. C.: Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Rad. Oncol. Biol. Phys., 32: 293, 1995.
16. SAS/STAT User's Guide, Version 6, 4th ed. Cary, NC: SAS Institute, Inc., 1990.
17. Fowler, F. J., Jr., Barry, M. J., Lu-Yao, G., Roman, A., Wasson, J. and Wennberg, J. E.: Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology, 42: 622, 1993.
18. Fowler, F. J., Jr., Barry, M. J., Lu-Yao, G., Wasson, J. H. and Bin, L.: Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J. Clin. Oncol., 14: 2258, 1996.
19. Albertsen, P. C.: Screening for prostate cancer is neither appropriate nor cost-effective. Urol. Clin. N. Amer., 23: 521, 1996.
20. Varenhorst, E., Carlsson, P. and Pedersen, K.: Clinical and economic considerations in the treatment of prostate cancer. Pharmacoeconomics, 6: 127, 1994.
21. Litwin, M.: Economic realities of prostate cancer management. Contemp. Urol., 9: 43, 1997.
22. D'Agostino, R. B. and Kwan, H.: Measuring effectiveness. What to expect without a randomized control group. Med. Care, suppl., 33: AS95, 1995.
23. Zietman, A. L., Shipley, W. U. and Coen, J. J.: Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. J. Urol., 152: 1806, 1994.
24. Barry, M. J.: Editorial: Proving early detection and treatment of prostate cancer does more good than harm: the need to support randomized trials actively. J. Urol., 152: 1903, 1994.
25. Gerber, G. S., Thisted, R. A., Scardino, P. T., Frohmuller, H. G., Schroeder, F. H., Paulson, D. F., Middleton, A. W., Jr., Rukstalis, D. B., Smith, J. A., Jr., Schellhammer, P. F., Ohori, M. and Chodak, G. W.: Results of radical prostatectomy in men with clinically localized prostate cancer. J.A.M.A., 276: 615, 1996.
26. Krongrad, A., Lai, H. and Lai, S.: Survival after radical prostatectomy. J.A.M.A., 278: 44, 1997.
27. Catalona, W. J., Smith, D. S., Ratliff, T. L. and Basler, J. W.: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J.A.M.A., 270: 948, 1993.
28. Hanks, G. E., Schultheiss, T. E., Hanlon, A. L., Hunt, M., Lee, W. R., Epstein, B. E. and Coia, L. R.: Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int. J. Rad. Oncol. Biol. Phys., 37: 543, 1997.
29. Ragde, H., Blasko, J. C., Grimm, P. D., Kenny, G. M., Sylvester, J. E., Hoak, D. C., Landin, K. and Cavanagh, W.: Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer, 80: 442, 1997.